All In Biotech

Drug Trial Radar · NCT05076149

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation

Last checked: Nov 19, 2026Latest source record: Jun 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 597 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

597

Actual

Start

Oct 27, 2021

Primary completion

May 18, 2023

Study completion Nov 30, 2023

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Oct 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and no F508del mutation.

Conditions

  • Cystic Fibrosis

Interventions

  • VX-121/TEZ/D-IVADrug

    Fixed-dose combination tablets for oral administration.

  • ELX/TEZ/IVADrug

    Fixed-dose combination tablets for oral administration.

  • IVADrug

    Tablet for oral administration.

  • Placebo (matched to VX-121/TEZ/D-IVA)Drug

    Placebo matched to VX-121/TEZ/D-IVA for oral administration.

  • Placebo (matched to ELX/TEZ/IVA)Drug

    Placebo matched to ELX/TEZ/IVA for oral administration.

  • Placebo (matched to IVA)Drug

    Placebo matched to IVA for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1second (ppFEV1)Time frame: From Baseline Through Week 24

Locations

170 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Banner University of Arizona Medical Center

    Tucson, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Children's Hospital of Orange County

    Orange, California

  • University of California Davis Medical Center

    Sacramento, California

  • Children's Hospital of Colorado

    Aurora, Colorado

  • National Jewish Health

    Denver, Colorado

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Nemours Children's Specialty Care

    Jacksonville, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Central Florida Pulmonary Group, PA

    Orlando, Florida

  • Nemours Children's Specialty Care, Pensacola

    Pensacola, Florida

  • Johns Hopkins All Children's Hospital Outpatient Care Center

    St. Petersburg, Florida

  • The Emory Clinic at Chantilly

    Atlanta, Georgia

  • St. Luke's Cystic Fibrosis Center of Idaho

    Boise, Idaho

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • Riley Hospital for Children at Indiana University Health

    Indianapolis, Indiana

  • University of Kentucky

    Lexington, Kentucky

  • Tulane Medical Center

    New Orleans, Louisiana

  • Maine Medical Partners

    Portland, Maine

  • Massachusetts General Hospital Cystic Fibrosis Center Clinical Rsearch Center

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • Michigan Medicine

    Ann Arbor, Michigan

  • Harper University Hospital

    Detroit, Michigan

  • Spectrum Health Medical Group Adult Cystic Fibrosis Care Center

    Grand Rapids, Michigan

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • The Children's Mercy Hospital

    Kansas City, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Billings Clinic

    Billings, Montana

  • Morristown Medical Center

    Morristown, New Jersey

  • CF Therapeutics Development Center of Western New York

    Buffalo, New York

  • Northwell Health- Long Island Jewish Medical Center

    New Hyde Park, New York

  • Columbia University Medical Center

    New York, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • Akron Children's Hospital

    Akron, Ohio

Showing 40 of 170 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.